Enriqueta Felip, MD, PhD, discusses how results from the phase 3 3475A-D77 trial evaluating subcutaneous pembrolizumab vs ...

Global Implantable Infusion Pump Market Set for Steady Growth from 2022 to 2032, Driven by Chronic Disease Management and Technological Advances.

The results showed comparable efficacy between the two formulations, with objective response rates of 24.2% vs 18.2% for subcutaneous and intravenous nivolumab, respectively. Safety profiles were ...

The autoinjector offers potential pain relief and is designed for self-administration, eliminating the need for refrigeration ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

The Trump administration is already gearing up for another round of Medicare drug price negotiations, while OpenAI launched a ...

CEO Dan O'Connell reported that Acumen completed enrollment of its 542-participant Phase 2 ALTITUDE-AD study evaluating Sabirnetug for early Alzheimer’s disease, stating, "We completed enrollment of ...

Drug major Johnson & Johnson (JNJ) announced Monday positive new data from the Phase 3 ASTRO study evaluating TREMFYA (guselkumab) subcutaneous (SC) induction therapy ...

The company targets topline results in late 2026 and continues to advance both intravenous and subcutaneous Sabirnetug development, supported by a strong cash position expected to fund operations ...

Halozyme is best known for its Enhanze subcutaneous delivery technology ... the top-selling cancer immunotherapy when the original intravenous infusion formulation falls off the patent cliff ...

Q1 2025 Earnings Call Transcript May 13, 2025 Acumen Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

A new treatment option for people with multiple sclerosis could alleviate resource strains on New Zealand's health system.